Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 4Phase 1 4

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 4Tumor-Agnostic 1

Conditions

Multiple Myeloma 95Recurrence 11Neoplasms, Plasma Cell 9Immunoglobulin Light-chain Amyloidosis 6Neoplasms 5Smoldering Multiple Myeloma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmacytoma 2Neoplasm, Residual 2Lymphoma 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Renal Insufficiency 1Prostatic Neoplasms 1Plasmablastic Lymphoma 1Paraproteinemias 1Non-small Cell Lung Cancer With STK11/LKB1 Mutation 1Myelodysplastic Syndromes 1Microsatellite Unstable Colorectal Cancer 1Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hypergammaglobulinemia 1Disease 1Chromosome 17 deletion 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × daratumumab × Clear all
NCT03899155 2026-05-27

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT01946477 2026-05-22

POM MM 014

Celgene

Phase 2 Completed
186 enrolled 17 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasmacytoma

NCT02626481 2026-04-07

IFM2014-04

University Hospital, Lille

Phase 2 Completed
64 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

NCT03314181 2025-08-14

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

AbbVie

Phase 2 Active not recruiting
156 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

US Oncology Research

Phase 2 Active not recruiting
73 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡